Prevail Therapeutics Inc (PRVL) Gets a Buy Rating from Cowen & Co.

By Austin Angelo

In a report released today, Yaron Werber from Cowen & Co. maintained a Buy rating on Prevail Therapeutics Inc (PRVLResearch Report). The company’s shares closed on Friday at $11.62.

According to TipRanks.com, Werber is a 4-star analyst with an average return of 12.2% and a 61.1% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Stoke Therapeutics Inc.

The the analyst consensus on Prevail Therapeutics Inc is currently a Moderate Buy rating.

See today’s analyst top recommended stocks >>

Based on Prevail Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $9.95 million. In comparison, last year the company had a GAAP net loss of $3.2 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson’s disease and other neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.